Table 1.
Clinical studies on the relationship between hair loss and COVID-19.
| Clinical Studies | Characteristics | Results | Year | References |
|---|---|---|---|---|
| Goren, A.; et al. | A descriptive study on 41 Caucasian males admitted to hospitals in Spain with a diagnosis of bilateral SARS-CoV-2 pneumonia (mean age = 58 years). | 71% of the subjects were diagnosed with significant MPHL of which 39% had a severe involvement. | 2020 | [15] |
| Wambier, C.G.; et al. | Multicenter study with a follow-up on 175 patients (males and females) hospitalized with COVID-19 | 79% (95% CI: 70–85%) of men and 42% (95% CI: 29–55%) of women had significant PHL. These values are in sharp contrast with the expected prevalence rates among age- and race-matched populations. The prevalence of MPHL in a similar white population is expected to be at 31–53%, and that of FPHL to be at a maximum of 38%. | 2020 | [16] |
| Wambier, C.G. | Reply to “Comment on androgenetic alopecia present in the majority of patients hospitalized with COVID-19” | The data available up to date points to a considerably higher prevalence and severity of PHL among hospitalized COVID-19 patients. | 2020 | [18] |
| Wambier, C.G.; et al. | Comparing study on androgenetic alopecia in COVID-19 on age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign. | Hypoxemia leading to skin ischemia is another potential pathogenetic factor that connects lung damage secondary to SARS-CoV-2 infection with hair growth impairment. | 2020 | [17] |
| Xiong, Q.; et al. | A single-center longitudinal study on 538 COVID-19 survivors and 184 controls in Wuhan, China: |
Almost half of the female participants started experiencing hair loss after being infected by SARS-CoV-2 compared to no case in the control group. 27% of affected cases experienced alopecia during their hospitalization while 73% first recognized it after being discharged. 3 to 4 months after discharge, alopecia was among the most prevalent complaints in convalescent COVID-19 patients, reported more commonly by women. Patients with higher stages of HL had worse clinical outcomes (use of ventilators and deaths). Some authors proposed the eponym ‘Gabrin sign’ to refer to the phenomenon of severe baldness in COVID-19 patients with a higher risk of unfavorable outcomes. |
2020 | [19] |